In 1967, Perley and Kipnis conducted a further study in which they showed that the insulin produced during the incretin effect in humans accounted for more than half of the total insulin secreted by oral glucose ingestion (Perley and Kipnis, 1967)
Similar content being viewed by others Introduction Glucagon-like peptide-1 (GLP-1) receptor agonists-based therapies function as glucose-lowering agents by mimicking the action of incretins, stimulating insulin secretion following oral glucose ingestion [1]
The right option depends on your lifestyle, activity level, and personal preference
Jakob Langer and Hiroshi Horio are employees of Novo Nordisk Pharma Ltd., Japan
From Report Problems to the Food and Drug Administration You are encouraged to report negative side effects of prescription drugs to the FDA
Most resolve as the body adjusts to the medication, typically within 1-4 weeks